InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board [Yahoo! Finance]
InMed Pharmaceuticals Inc. - Common Shares (INM)
Company Research
Source: Yahoo! Finance
the research, development, manufacturing, and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced the addition of Dr. David G. Morgan, a renowned leader in neurodegenerative disease to its Scientific Advisory Board ("SAB") reinforcing the Company's commitment to advancing it's INM-901 program in the treatment of Alzheimer's disease. Eric Hsu, InMed's SVP of Preclinical Drug Development, commented, "We are privileged to welcome someone of Dr. Morgan's stature to our SAB, which underscores the recent progress we've achieved in the INM-901 program. Dr. Morgan's significant contributions and pioneering breakthroughs have made him a leading authority in Alzheimer's research. His guidance and expertise will be invaluable as we advance to the next stages of development of our INM-901 program in the treatment of Alzheimer's." Biography Dr. David Morgan is Director of the Alzheimer's Alliance and MSU Foundation Professor of Translational Neuroscien
Show less
Read more
Impact Snapshot
Event Time:
INM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INM alerts
High impacting InMed Pharmaceuticals Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
INM
News
- InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration [Yahoo! Finance]Yahoo! Finance
- InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies [Yahoo! Finance]Yahoo! Finance
- InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance [Yahoo! Finance]Yahoo! Finance
- InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
INM
Sec Filings
- 4/18/24 - Form 8-K
- 4/16/24 - Form 8-K
- 4/5/24 - Form 8-K
- INM's page on the SEC website